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A Novel G-Subunit Inhibitor Selectively Modulates
-Opioid-Dependent Antinociception and Attenuates
Acute Morphine-Induced Antinociceptive Tolerance
and Dependence
Jennifer L. Mathews, Alan V. Smrcka, and JeanM. Bidlack
Department of Pharmacology and Physiology, University of Rochester, School of Medicine and Dentistry, Rochester, New York 14642-8711
TheG subunit has been implicated inmany downstream signaling events associatedwith opioids.We previously demonstrated that a
small molecule inhibitor of G-subunit-dependent phospholipase (PLC) activation potentiatedmorphine-induced analgesia (Bonacci
et al., 2006). Here, we demonstrate that this inhibitor, M119 (cyclohexanecarboxylic acid [2-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)-
(9Cl)]), is selective for -opioid receptor-dependent analgesia and has additional efficacy in mouse models of acute tolerance and
dependence. When administered by an intracerebroventricular injection in mice, M119 caused 10-fold and sevenfold increases in the
potencies of morphine and the -selective peptide, DAMGO, respectively. M119 had little or no effect on analgesia induced by the 
agonist U50,488 or  agonists DPDPE or Deltorphin II. Similar results were obtained in vitro, as only activation of the-opioid receptor
stimulated PLC activation, whereas no effect was seen with the - and -opioid receptors. M119 inhibited -receptor-dependent PLC
activation. In studies to further explore the in vivo efficacy of M119, systemic administration M119 also resulted in a fourfold shift
increase in potency of systemically administeredmorphine. Of particular interest,M119was also able to attenuate acute, antinociceptive
tolerance and dependence in mice treated concomitantly with both M119 and morphine. These studies suggest that small organic
molecules, such as M119, that specifically regulate G subunit signaling may have important therapeutic applications in enhancing
opioid analgesia, while attenuating the development of tolerance and dependence.
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Introduction
Opioid analgesics are clinically important for the treatment of
moderate to severe pain. The three types of opioid receptor,, ,
and , are G-protein-coupled receptors that activate Gi, resulting
in inhibition of adenylyl cyclase activity (Sharma et al., 1977),
activation of inwardly rectifying K channels (North et al.,
1987), inhibition of voltage-activated Ca2 channels (Moises et
al., 1994), and the activation ofmitogen-activated protein kinase,
extracellular signal-regulated ERK-1/2 kinases (Law et al., 2004),
and phosphatidylinositol (PI)-specific phospholipase C (PLC)
(Xie et al., 1999). Recently, the importance of G-mediated
activation of PI-PLC in the potentiation of opioid analgesia has
been examined (Xie et al., 1999; Galeotti et al., 2006).
Activation of PLC results in hydrolysis of phosphatidylinosi-
tol 4,5-bisphosphate to the two signaling molecules, inositol-
1,4,5-triphosphate, which mobilizes Ca2 from intracellular
stores, and diacylglycerol, which activates protein kinaseC (PKC)
(Rebecchi and Pentyala, 2000). PLC2 and PLC3 isoforms are
activated by G and are responsible for phosphatidylinositol
(PI) hydrolysis stimulated by Gi-coupled receptors, with PLC2
being expressed primarily in hematopoietic cells (Rhee and Bae,
1997).
Previous data from our laboratories suggested that pharma-
cological inhibition of PLC3might enhance opioid-induced an-
tinociception (Xie et al., 1999). In these experiments with PLC3
knock-out mice, the mice lacking PLC3 had a 10-fold potenti-
ation inmorphine-induced antinociception compared with con-
trol animals. This finding was one of the first indications that this
pathway may be an important regulator of opioid signaling and
subsequent analgesic responsiveness, and indicated that targeting
PLC3 or PLC3 regulation pharmacologically could influence
opioid efficacy.
Recently, we reported on a series of novel G inhibitors
(Bonacci et al., 2006). From screening of a smallmolecule library,
several compounds were found that bound to G subunits and
selectively inhibited G subunit signaling. The lead compound
in the series, M119 (cyclohexanecarboxylic acid [2-(4,5,6-
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trihydroxy-3-oxo-3H-xanthen-9-yl)-(9Cl)]), had high affinity
for the G subunit and was an inhibitor of PLC3 signaling in
vitro. In vivo, coadministration ofM119 [100 nmol, intracerebro-
ventricular (i.c.v.)] with graded doses of morphine (i.c.v.) re-
sulted in a 10-fold leftward shift in the morphine antinociceptive
dose–response curve (Bonacci et al., 2006), similar to the shift
that had been seen with the PLC3 knock-out mice (Xie et al.,
1999). Administration of M119 with morphine in the PLC3
knock-out mice had no additional effect (Bonacci et al., 2006),
further supporting the hypothesis that the mechanism of action
for M119 was through the attenuation of opioid-induced activa-
tion of PLC3 by G. It is important to note that morphine still
produced an analgesic response in the animals which had been
administeredM119, suggesting that regulation of other G tar-
gets was still intact. This would be of particular importance in the
activation of inwardly rectifying K channels, which are medi-
ated by G and thought to play an important role in
antinociception.
Selectively inhibiting downstream signaling from the G
subunit, with a small molecule inhibitor, is a novel approach to
targeting only a pathway of interest, while leaving the rest of the
signaling machinery intact. The goal of this current study was to
determine the effect M119 would have in vivo, not only on an-
tinociception mediated by all three opioid receptors, but also in
models of acute analgesic tolerance and dependence.
Materials andMethods
Animals.Male, ICR mice (20–30 g) (Harlan Industries) were housed in
groups of five with food and water available ad libitum before any pro-
cedures. Animals were maintained on a 12 h light/dark cycle in a
temperature-controlled animal colony. Studieswere performed in accor-
dance with the Policies on the Use of Animals in Neuroscience Research.
Chemicals.M119 (Fig. 1) was obtained from the chemical diversity set
from the Developmental Therapeutics Program from the NCI/NIH.
M119 is referenced as compound NSC 119910 within that series. M119
was used as directly supplied by NCI/NIH. Morphine sulfate was pur-
chased from Mallinckrodt. [D-Ala 2,N-Me-Phe4,Gly 5-ol]-enkephalin
(DAMGO), [D-Pen2,D-Pen5]enkephalin (DPDPE), [D-Ala 2]-
Deltorphin II (Deltorphin II), (trans)-3,4-dichloro-N-methyl-N-[2-(1-
pyrrolidinyl)-cyclohexyl]benzeneacetamide methane-sulfonate hydrate
(U50,488), -funaltrexamine (-FNA), and naloxone were purchased
from Sigma.
Inositol phosphate assay using hMOR-CHO, hKOR-CHO, and hDOR-
CHO cells. Chinese hamster ovary (CHO) cells stably expressing the hu-
man  (hKOR-CHO),  (hDOR-CHO) (L. Toll, Stanford Research In-
stitute, Palo Alto, CA), or  (hMOR-CHO) (G. Uhl, National Institute
on Drug Abuse, Baltimore, MD) opioid receptor were used in the exper-
iments. Cells in six-well plates were labeled by adding 4 Ci of [ 3H]i-
nositol for 24 h in inositol-free F-10 media, without serum. After label-
ing, LiCl was added directly to the labelingmedia at a final concentration
of 10 mM. Ligands or peptides were added at the same time. The final
volumeof eachwell was 1ml. The plateswere put back in to the incubator
at 37°C for 30 min, after which time the medium was aspirated and the
plates were washed twice with PBS. Ice-cold 50mM formic acid, 1ml, was
added to the plates which were placed in the cold room at 4°C for 30min.
After the incubation, the contents of the plates were applied to Dowex
AG1-X8 columns and allowed to flow all the way through the column.
The columns were washed, twice each, with 50 and 100 mM formic acid,
for a total of four washes, followed by elution of the inositol phosphate
(IP)-containing fraction with 3 ml of 1.2 M ammonium formate/0.1 M
formic acid. The eluted fraction was mixed with Scintisafe scintillation
fluid (Fisher Scientific), for high salt, and counted. The data are repre-
sented as the fold increase over control in total inositol phosphates. All
experiments were repeated three times and performed in duplicate. Con-
trol cells for each experiment were labeled with [ 3H]inositol and LiCl, in
the same manner as the treatment groups.
Drug solutions and injections. For i.c.v. injections, M119 was initially
solubilized inDMSO and all subsequent dilutions were in distilled water.
For systemic intraperitoneal (i.p.) injections, M119 was initially solubi-
lized in a small volume of NaOH and brought to volume in PBS to pH
7.5. Vehicle was prepared in a similar manner without the drug. Addi-
tional compounds used in these studies were dissolved in the same vehi-
cle as M119 for both i.c.v. and systemic injections. Intracerebroventric-
ular injections were made directly into the lateral ventricle according to
the modified method of Haley and McCormick (1957). The mouse was
lightly anesthetized with ether, an incision wasmade in the scalp, and the
injection was made 2 mm lateral and 2 mm caudal to bregma at a depth
of 3 mm using a 10 l Hamilton syringe. The volume of all i.c.v. injec-
tions was 5 l.
Antinociceptive testing. Antinociception was assessed using the 55°C
warm-water tail-flick test. For the tail-flick test, the latency to the first
sign of a rapid tail flick was taken as the behavioral endpoint (Jannsen et
al., 1963). Each mouse was first tested for baseline latency by immersing
its tail in thewater and recording the time to response.Mice not respond-
ing within 5 s were excluded from further testing.Mice were then admin-
istered the test compound and tested for antinociception 20min after the
injection. A maximum score was assigned (100%) to animals not re-
sponding within 15 s to avoid tissue damage. Antinociception was calcu-
lated by the following formula: % antinociception  100  (test la-
tency control latency)/(15 control latency).
Effects of M119  receptor-selective agonists. Mice were treated con-
comitantly with M119 (100 nmol, i.c.v.) and graded doses of receptor
selective agonists (DAMGO,U50,488, DPDPE, andDeltorphin II). Con-
trol mice received a vehicle injection (i.c.v.,20 min). Antinociception
was assessed 20 min after agonist injection. To test the effects of M119
systemically,mice receivedM119 (100mg/kg, i.p.) followed immediately
by graded doses of morphine subcutaneous (s.c.). Antinociception was
tested 20 min after the agonist injection.
Acute antinociceptive tolerance. For quantitative measurements of
acute opioid tolerance, a standardized state of tolerance was induced by
administration of morphine at times 0, 2 h, 4 h, and 6 h. The degree of
tolerance was calculated from the shift in ED50 value from the nontoler-
ant state to the tolerant condition (Way et al., 1969). All injections were
i.c.v., and antinociception was assessed 20 min after each injection. Mice
were lightly anesthetized before each injection. Previous reports have
indicated that this dosing schedule induced acute morphine tolerance
(Jiang et al., 1995). To assess the role of M119 in acute morphine toler-
ance, M119 and morphine were administered concomitantly at times 0,
2 h, 4 h, and 6 h. Time 0 is defined as the first injection of agonist.
Acute physical dependence. To assess development of acute morphine
physical dependence (Yano and Takemori, 1977; Bilsky et al., 1996;
Wang et al., 1999), mice were pretreated with a single injection of mor-
phine (100mg/kg, s.c.,4 h). Before the administration of naloxone (30
min), mice were injected with vehicle, i.c.v. Withdrawal was precipitated
by an injection of the opioid antagonist, naloxone (10 mg/kg, i.p.). Mice
Figure1. Chemical structureof thenovelG inhibitorM119,whichwasobtained fromthe
NCI diversity set (reference number NSC 119910).
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were immediately placed in a clear cylinder and observed for 15min. The
number of vertical jumps was recorded during this time. To test whether
M119 affected morphine physical dependence, the same treatment as
described above was used with M119 (100 nmol, i.c.v.) being adminis-
tered 30 min before the administration of naloxone.
Receptor binding assays. The receptor binding assay was performed
with membranes from hMOR-CHO cells using the -selective radioli-
gand [3H]DAMGO. Binding was performed in 50mM Tris-HCl, pH 7.5,
at 25°C for 60 min with varying concentrations of M119. Membrane
protein (50 g of hMOR-CHO) was incubated in 50 mM Tris-HCl, pH
7.5 in a final volume of 1 ml with 0.25 nM [3H]DAMGO and varying
concentrations of M119. Nonspecific binding was determined in the
presence of 10 M naloxone. After a 60 min incubation at 25°C, the
membranes were filtered onto No. 32 glass by vacuum filtration, fol-
lowed by three washes with 3 ml of ice-cold 50 mM Tris-HCl, pH 7.5.
Samples were counted in 2 ml of Scintsafe 30% scintillation fluid.
cAMP assay. To measure cAMP, hMOR-CHO cells were grown in
12-well plates and incubated with 1 M forskolin, 100 M isobutylmeth-
ylxanthine (IBMX), and varying concentrations of M119, in serum-free
DMEMmedia for 20 min. After the incubation, the plates were immedi-
ately placed on ice and the cells were washed with PBS and lysed with
0.1N HCl. cAMP was extracted and quantified, following the manufac-
turer’s instructions, using the cAMP EIA direct assay kit from Assay
Design. Data are represented as percentage of cAMP over control.
Statistical analysis. Data from dose–response experiments were fitted
to a sigmoidal dose–response model using nonlinear regression analysis,
and ED50 values and 95% confidence limits (CL) were calculated. A shift
in the dose–response curve was determined from the ED50 values. To
assess whether the ED50 or IC50 values for two dose–response or
concentration-response curves were significantly different, an F test was
performed (GraphPad Prism 4.03). Values are reported as two-tailed p
values. Statistical significance was set at p 0.05. All data points are the
mean of 7–10 mice, with SEM represented by error bars. Statistical anal-
ysis of the acute dependence data and inositol phosphate data used the
Student’s t test.
Results
The G inhibitor, M119, potentiated-opioid
receptor-mediated antinociception
Previous data from our lab demonstrated that PLC3, a G
subunit-regulated enzyme, was a negative modulator of
-opioid-dependent signaling (Xie et al., 1999). We therefore
predicted that inhibiting -dependent PLC3 activation would
potentiate-opioid-mediated antinociception, in amanner sim-
ilar to the PLC3 knock-out studies (Xie et al., 1999; Bonacci et
al., 2006). Previously, we observed that coadministration of
M119 (Fig. 1) with morphine resulted in a significant ( p 
0.001), 10-fold potentiation in morphine-mediated antinocicep-
tion (Bonacci et al., 2006) (Fig. 2A). To determine whether the
effects ofM119were specific tomorphine,M119was also admin-
istered with agonists selective for the , , and  receptors. Co-
administration of M119 and the -selective agonist, DAMGO,
resulted in a sevenfold leftward shift in the DAMGO dose–r-
esponse curve when compared with DAMGO alone ( p 0.001)
(Fig. 2B). DAMGOalone produced an ED50 value and 95%CL of
0.07 nmol (0.03–0.17 nmol), whereas DAMGO and M119 re-
sulted in an ED50 value and 95% CL of 0.01 nmol (0.005–0.03
nmol). A modest, twofold, shift was observed in the dose–re-
sponse curve of the -selective agonist, U50,488, when adminis-
tered with M119 ( p  0.01) (Fig. 3A). The ED50 values for
U50,488 alone and U50,488 with M119 were 37 nmol (29–47
nmol) and 17 nmol (9.4–31 nmol), respectively. M119 did not
potentiate antinociception mediated through either 1 or 2 re-
ceptor. The ED50 values for the 1-specific agonist, DPDPE, alone
or with M119 did not change significantly, 6.5 nmol (2.6–16
nmol) and 5.4 nmol (2.6–11 nmol), respectively (Fig. 3B). The
2-selective agonist, Deltorphin II, produced an ED50 value of 11
nmol (5.5–23 nmol) which was unchanged in the presence of
M119, 11 nmol (5.1–23 nmol) (Fig. 3C). Administration ofM119
alone had no effect on baseline tail-withdrawal latencies (Bonacci
et al., 2006). These experiments demonstrated that M119 selec-
tively potentiated -opioid-dependent antinociception.
To determine whetherM119 would be effective after systemic
administration, M119 was administered i.p. followed immedi-
ately with a s.c. injection of morphine. Systemic administration
ofmorphine alone produced an ED50 value of 5.0mg/kg (2.9–8.4
mg/kg), which was shifted fourfold to the left in the presence of
M119, producing an ED50 value of 1.3 mg/kg (0.59–2.8 mg/kg)
( p 0.001) (Fig. 4).
M119 inhibition of IP productionmediated by the
-opioid receptor
We previously proposed that the potentiation in morphine-
induced antinociception was caused by M119 inhibition of -
dependent PLC3 (Bonacci et al., 2006). To demonstrate that
M119 blocked -opioid receptor-dependent PLC activation, we
measured morphine- and DAMGO-dependent total inositol
phosphate (IP) production in hMOR-CHO cells. Both DAMGO
(10 M) and morphine (10 M) significantly increased total IP
measured compared with control, with a fourfold and threefold
increase, respectively ( p  0.01) (Fig. 5A). This increase was
significantly attenuated with the addition of the  inhibitor,
M119 (10 M) ( p 0.05), whereas M119 had no effect by itself.
The -selective antagonist, -FNA also attenuated DAMGO-
and morphine-dependent IP production (Fig. 5A) ( p  0.05).
The effect of M119 on DAMGO-stimulated IP generation was
concentration dependent (Fig. 5B). Maximal M119 effects were
observed at 10 M ( p  0.05) and 30 M ( p  0.01). The
-selective agonist, U50,488 (10M) and the -selective agonists,
DPDPE (10 M) had no effect on IP production alone or in the
presence of M119 in the hMOR-CHO cells (data not shown).
These data demonstrate that the-opioid receptor can stimulate
PLC activation and that this coupling was blocked by M119.
To determine whether other opioid receptors couple to PLC
activation, we examined opioid receptor-dependent IP genera-
tion in hDOR-CHO and hKOR-CHO cells. In the hDOR-CHO
cells neither DPDPE (10 M) or Deltorphin II (10 M) signifi-
cantly increased IP generation over control treated cells (Fig. 5C).
Figure 2. Effect of M119 on antinociception mediated by the-opioid receptor. Coadmin-
istration of M119 (100 nmol, i.c.v.) with morphine (0.01–3 nmol, i.c.v.) resulted in a 10-fold
potentiation ofmorphine-induced antinociception (p 0.001) (A). The graphwas reproduced
with permission fromBonacci et al. (2006), their Figure 4. Concomitant administration ofM119
(100 nmol) with the -selective agonist, DAMGO (0.01–0.1 nmol), resulted in a sevenfold
leftward shift in ED50 value comparedwithDAMGOalone (p0.001) (B). All datapoints are the
mean of 7–10mice, with SEM represented by error bars. Antinociception was assessed 20 min
after agonist and M119 injection in the 55°C warm-water tail-flick test.
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Treatment with M119 (10 M) and the -selective antagonist,
naltrindole (100 M) also had no significant effect (Fig. 5C).
Treatment withU50,488 (10M), with or withoutM119 (10M)
or nor-BNI (10 M), the -selective antagonist, in the hKOR-
CHOcells had no significant effect on IP production over control
treated cells (Fig. 5D). Importantly, the levels of opioid receptors
were the same for all three cell lines (Bmax values not significantly
different, data not shown). These in vitro data correlate with the
effects of M119 in vivo, where only in the mice treated with the
-preferring compounds was a significant potentiation in an-
tinociception observed. It is possible that the selective effects of
M119 observed in vivo on -opioid receptor-dependent antino-
ciception are the result of selective coupling of-opioid receptor
to G-dependent PLC activation.
Effect of M119 on acute morphine antinociceptive tolerance
As an initial test of the efficacy of M119 in reducing the develop-
ment of morphine antinociceptive tolerance, an acute tolerance
assay was performed. We used this assay to measure tolerance
because it requires considerably less compound than traditional
tolerance paradigms, while still yielding reliable results. The an-
tinociceptive effect of repeated (0, 2, 4, 6 h) doses (1–10 nmol) of
morphine and the development of acute antinociceptive toler-
ance are shown in Figure 6A. Morphine produced dose-
dependent antinociception in the 55°C warm-water tail-flick as-
say. The ED50 value (95% CL) for i.c.v. morphine at time 0 was
0.59 nmol (0.16–2.2 nmol). After repeated administration, acute
morphine antinociceptive tolerance developed by 4 h with a sig-
nificant shift in the ED50 value ( p 0.01). At 4 h, the ED50 value
had shifted eightfold, 4.9 nmol (1.8–13 nmol) and by 6 h, the
ED50 value had shifted 16-fold, 9.6 nmol (3.2–29 nmol) ( p 
0.001). Coadministration of M119 with morphine greatly atten-
uated acute morphine antinociceptive tolerance (Fig. 6B). The
ED50 values remained virtually unchanged, with no statistical
difference, from time 0, 0.16 nmol (0.02–1.3 nmol) to the 6 h time
point, 0.22 nmol (0.008–5.7 nmol). Control mice were treated
under the same injection protocol, however, received only vehi-
cle. No significant change from baseline tail-withdrawal values
were observed for any of the control mice at any of the times
tested (data not shown), indicating that the procedure used in the
acute tolerance protocol was not contributing to the data which
was observed.
Effect of M119 on acute morphine physical dependence
In an acute model of morphine dependence, mice were treated
with morphine (100 mg/kg, s.c., 4 h), followed by M119 (100
Figure 3. Effect of M119 on antinociception mediated by the - and -opioid receptors. A
moderate, twofold, leftward shift in ED50 value was observed with coadministration of M119
(100 nmol, i.c.v.) and the -selective, agonist, U50,488 (10–60 nmol, i.c.v.) compared with
U50,488 alone (p 0.01) (A). Coadministration of M119 with either the 1-selective agonist,
DPDPE (3–30 nmol, i.c.v.) (B) or the 2-selective agonist, Deltorphin II (1–10 nmol, i.c.v.) (C),
did not result in a shift of the ED50 value compared with either agonist alone. Antinociception
was assessed 20 min after agonist and M119 injection in the 55°C tail-flick test. All data points
are the mean of 7–10 mice, with SEM represented by error bars.
Figure 4. Effect of systemic administration of M119 on morphine-induced antinociception.
Systemic administration of M119 (100 mg/kg, i.p.) with graded doses of morphine (1–10 mg/
kg, s.c.) resulted in a potentiation of antinociception asmeasured by a fourfold leftward shift in
the ED50 value comparedwithmorphine alone (p 0.01). All data points are themean of 7–10
mice, with SEM represented by error bars. Antinociception was assessed 20 min after agonist
injection in the 55°C warm-water tail-flick test.
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nmol, i.c.v.) or vehicle (i.c.v.) 30min before naloxone (10mg/kg,
i.p.), which resulted in withdrawal jumping. Control mice
jumped an average of 71  12 times in the 15 min counting
period (Fig. 7). Mice treated withM119 jumped significantly less
times in the 15 min counting period, an average of 23  14
compared with 71  12 for the control mice (Fig. 7). Post hoc
analysis (Student’s t test) indicated that coadministration of
M119 30 min before naloxone administration produced signifi-
cantly less vertical jumps than vehicle administration before nal-
oxone ( p 0.05).
Effects of M119 on opioid receptor binding and
downstream signaling
It was important to demonstrate that increasing concentrations
ofM119 did not inhibit the ability of an opioid agonist to bind the
receptor. Receptor binding assays were performed to address
whether M119 mediated its effects through direct binding and
activation of the opioid receptors. Increasing concentrations of
M119 were incubated with the-selective peptide [3H]DAMGO
in membranes from hMOR-CHO cells. M119 did not signifi-
cantly inhibit [3H]DAMGO binding to
the -opioid receptor at any concentra-
tion tested (Fig. 8A).
It is well established that all three types
of opioid receptors activate Gi, resulting in
inhibition of adenylyl cyclase activity
(Sharma et al., 1977; Childers, 1991).
Therefore, if the receptor is in fact signal-
ing effectively, this would be reflected as an
inhibition of cAMP levels. Previous in vitro
studies with M119 had suggested that the
compound did not prevent the heterotri-
meric G-protein from reassembling
(Bonacci et al., 2006). However, it was un-
clear whether M119 would potentiate the
downstream opioid effects on cAMP.
hMOR-CHO cells were treated with
forskolin and IBMX to stimulate cAMP
production. The -selective agonist,
DAMGO, concentration-dependently in-
hibited cAMP levels with an IC50 value of
24 3.6 nM (Fig. 8B). Concomitant treat-
ment of cells with DAMGO andM119 (10
M) did not potentiate this effect as shown
by the IC50 value of 26 2.9 nM (Fig. 8B).
A similar effect was observed with mor-
phine (data not shown). The general opi-
oid antagonist, naloxone, reversed the ef-
fects of both DAMGO and morphine
indicating that both agonists were inhibit-
ing cAMP production through an opioid-
mediated pathway (data not shown).
Discussion
In the current study, our laboratory took
the novel approach of using a G inhib-
itor to influence the efficacy and potency
of morphine in several animal models of
-opioid receptor function. Our funda-
mental hypothesis for the mechanism of
action of this compound is based on stud-
ies conducted by Xie et al. (1999) demon-
strating that the G-dependent enzyme,
PLC3, was a negative modulator of
-opioid receptor signaling both in PLC3 knock-out mice and
in dorsal root ganglion neurons. We demonstrated previously
that the G inhibitor, M119, inhibited the activation of PLC3
byG in vitro and that concomitant administration of this novel
compound with morphine in vivo resulted in a 10-fold shift in
morphine analgesic potency, virtually identical, to data from the
PLC3 knock-out studies (Xie et al., 1999; Bonacci et al., 2006).
In addition, M119 had no effect in PLC3 knock-out mice, fur-
ther supporting in vitro evidence that M119 was blocking the
binding of G to PLC3 (Bonacci et al., 2006).
Here, we explored further the specificity and underlying
mechanisms of action ofM119 in potentiating analgesia as well as
presented evidence extending the potential therapeutic efficacy of
this approach.
M119 displayed-opioid receptor selectivity in vivo
Increased analgesic potency was observed in mice treated with
M119 and morphine and also M119 and the receptor-selective
agonist, DAMGO. Minimal effects were observed with - and
Figure 5. The effects of-,-, and-selective opioid agonists andM119 on IP production in CHO cells stably expressing one
of the human opioid receptors. IP levels weremeasured as described inMaterials andMethods. The agonists, DAMGO (10M)
and morphine (10 M), both significantly increased the total inositol phosphates measured in hMOR-CHO cells (**p 0.01)
comparedwith control (A). The-selective antagonist-FNA (10M) attenuated this response (*p 0.05) comparedwith the
agonist alone.M119 inhibition of DAMGO-stimulated IP generationwas concentration dependent [10M (*p0.05) and30M
(**p 0.01), compared with DAMGO alone] (B). In the hDOR-CHO cells, neither-selective agonist, DPDPE (10M) nor Deltor-
phin II (10M) significantly increased IP generation over control treated cells (C). M119 and naltrindole (NTI) also had no effect in
the hDOR-CHO cells. The-selective agonist, U50,488 (10M), had no significant effect on IP generation with or without M119
(10M) or nor-BNI (10M) in the hKOR-CHO cells (D).
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-selective agonists, U50,488, DPDPE, and Deltorphin II. These
studies indicated that M119 was selective, in vivo, for the poten-
tiation of -mediated analgesia. Similar results were obtained
from the in vitro IP assay, with only the agonists, DAMGO and
morphine, stimulating IP generation which was inhibited by
M119. We propose that the - and -opioid receptors do not
activate the same PLC isoforms, or are not acting in the same
brain regions, and therefore are not inhibited by the same PLC-
dependent feedback pathway observed for the -opioid receptor
and it is for this reason that that M119 lacks efficacy with these
receptors.Why three receptors that couple to the sameGi protein
have differential effects on PLC activation is unclear and will
require further investigation.
Galeotti et al. (2006) recently demonstrated the importance of
PLC3 in opposing morphine analgesia using antisense phos-
phodiester oligonucleotides specifically to PLC3. In mice
treated both with morphine and the antisense oligonucleotide, a
potentiation in analgesic response was observed (Galeotti et al.,
2006). The same group also demonstrated localization of PLC3
in regions of the brain important for nociceptive transmission
which have been previously shown to also express the -opioid
receptor (Galeotti et al., 2006).
Downstream signaling and the role of phospholipids in
tolerance and dependence
There is evidence that the PLC pathway can influence the devel-
opment of opioid tolerance and dependence. Inhibitors of PLC
(Smith et al., 1999), IP3 receptors (Smith et al., 1999), and PKC
(Bilsky et al., 1996; Smith et al., 1999; Bohn et al., 2002) all atten-
uated morphine tolerance. PKC knock-out animals also exhib-
ited attenuatedmorphine tolerance (Zeitz et al., 2001). It has also
been suggested that generation of IP3 and DAG along with acti-
vation of PKC may be important for the development of opioid
dependence (Fundytus and Coderre, 1996; Smith et al., 1999). In
the current studies, M119 attenuated both acute antinociceptive
tolerance and dependence, but which of these specific mecha-
nisms downstream of -dependent PLC3 regulation are re-
sponsible for these effects remains to be defined. Additionally, it
will be important to study the effect of M119 on chronic
morphine-antinociceptive tolerance and dependence.
Specificity and underlying mechanisms of action of M119
in vitro
Previous studies from our lab tested the effects of differentially
targetingG signaling in intact cells.M119was shown to inhibit
activation of phosphoinositide 3 kinase  (PI3K) and fMLP-
induced Ca2 increases in differentiated HL-60 leukocytes
(Bonacci et al., 2006). The fMLP receptor couples to Gi in the
HL-60 cells. Importantly, M119 had no effect on carbachol-
dependent increases in Ca2 in HEK293 cells stably expressing
the Gq-linked M3-muscarinic receptor, confirming a specific ef-
fect of M119 on G-dependent Ca2mobilization (Bonacci et
al., 2006). These data suggest that M119 was in fact penetrating
into the cell to produce an effect through a -mediated mecha-
nism. Our current studies demonstrated that M119 did not in-
hibit [3H]DAMGO binding to the-opioid receptor at any con-
centration tested. As ameans to address whether the receptor was
signaling as expected, we performed a cAMP assay. The IC50
value for DAMGO was not significantly changed in the presence
Figure 6. Effect of M119 on acutemorphine antinociceptive tolerance. In an acutemodel of
morphine antinociceptive tolerance,morphinewas administered at times 0, 2, 4, 6 h (A). At 4 h,
significant tolerance (p 0.01) had developed as measured by an eightfold shift in the ED50
value and by 6 h, a 16-fold shift in the ED50 value was measured (p 0.001). Concomitant
administration of M119 (100 nmol, i.c.v.) and graded doses of morphine attenuated acute
morphine antinociceptive tolerance at all time points tested (B). Both compoundswere admin-
istered at times 0, 2, 4, 6 h. No significant change in the ED50 values was determined. Antinoci-
ception was assessed 20min after each injection in the 55°C tail-flick test. Control mice had no
change from baseline tail-withdrawal latencies at any of the time points tested (data not
shown).
Figure 7. Effect of M119 onmorphine-induced physical dependence. In a measure of acute
morphine dependence, mice were administered morphine (100 mg/kg, s.c.,4 h) and with-
drawal was precipitated by injection of naloxone (10 mg/kg, i.p.). Withdrawal jumping was
counted for 15min after antagonist injection. Injection ofM119 (100 nmol, i.c.v.) 30min before
the injection of naloxone resulted in significantly less vertical jumps thannaloxone alone (*p
0.05).
Figure 8. Effect of M119 on [ 3H]DAMGO binding to the -opioid receptor (A) and on
DAMGO-induced inhibition of cAMP levels (B). hMOR-CHO membranes were incubated with
0.25 nM [ 3H]DAMGO and varying concentrations of M119 as described in Materials and Meth-
ods. M119 did not significantly inhibit [ 3H]DAMGO binding to the hMOR (A). DAMGO inhibited
forskolin-stimulated cAMPproduction and this effectwasnot potentiatedby the additionof the
 inhibitor, M119 (B). hMOR-CHO cells were treated with varying concentrations of DAMGO
along with 10M forskolin and 100 mM IBMX, with and without 10M M119. DAMGO dose-
dependently inhibited cAMP (IC50 24 3.6 nM), and concomitant treatment of cells with
DAMGO and 10M M119 did not potentiate this effect (IC50 26 2.9 nM).
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of M119. Additionally, M119 produced a concentration-
dependent inhibition of IP generation in hMOR-CHO cells
treated with either DAMGO or morphine.
In conclusion, we demonstrated that selectively inhibiting
G signaling represents a novel approach to target only the
effector of interest, in this case, PLC3, while leaving other sig-
naling pathways intact. This approach represents a novel strategy
for potentiating opioid efficacy and also attenuating morphine
tolerance and dependence.
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